The invention relates to the treatment of inflammatory bowel disease, alsotermed IBD, including ulcerative colitis and Crohn's disease. To this end, theinventionproposes clinoptilolite having a particle size between 0.2 and 1 µm for usein thetreatment of inflammatory bowel disease, also termed IBD, in mammals andhumans. Inthe case of such use, the clinoptilolite is preferably freed of heavy metals.In onevariant, it is administered orally, optionally with pharmaceutically harmlesscarriermaterials and/or diluents.
